Stern R S
Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
J Am Acad Dermatol. 2001 May;44(5):755-61. doi: 10.1067/mjd.2001.114576.
Oral methoxsalen (psoralen) and ultraviolet A radiation (PUVA) is a highly effective therapy for psoriasis and many other skin conditions. It is carcinogenic. Previously we reported an increased risk of melanoma that first emerged 15 years after first treatment.
Our purpose is to present additional data concerning the associations of previous exposure to PUVA, the passage of time, and the risk of malignant melanoma.
We have prospectively studied a cohort of 1380 patients first treated with PUVA in 1975 and 1976. We have documented the occurrence of melanoma and in this report compare the observed and expected incidence of melanoma in this cohort, particularly melanomas developing since our earlier report (ie, after March 1996).
Since 1975, 23 patients have developed 26 invasive or in situ cutaneous melanomas. In an average of 2.25 years since our last report, we detected 7 additional invasive melanomas (incidence rate ratio, 8.4; 95% confidence interval, 3.4-17.3).
Beginning 15 years after first exposure to PUVA, an increased risk of melanoma is observed in our cohort of PUVA-treated patients. This risk is greater in patients exposed to high doses of PUVA, appears to be increasing with the passage of time, and should be considered in determining the risks and benefits of this therapy.
口服甲氧沙林(补骨脂素)及紫外线A光照射(PUVA)是治疗银屑病和许多其他皮肤病的一种高效疗法。它具有致癌性。此前我们报告称,首次治疗15年后首次出现黑色素瘤风险增加。
我们的目的是提供更多关于既往接触PUVA、时间推移与恶性黑色素瘤风险之间关联的数据。
我们对1975年和1976年首次接受PUVA治疗的1380例患者队列进行了前瞻性研究。我们记录了黑色素瘤的发生情况,在本报告中比较了该队列中黑色素瘤的观察发病率和预期发病率,特别是自我们早期报告(即1996年3月之后)以来发生的黑色素瘤。
自1975年以来,23例患者发生了26例侵袭性或原位皮肤黑色素瘤。自我们上次报告以来的平均2.25年里,我们又检测到7例侵袭性黑色素瘤(发病率比为8.4;95%置信区间为3.4 - 17.3)。
在首次接触PUVA 15年后开始,我们接受PUVA治疗的患者队列中观察到黑色素瘤风险增加。高剂量PUVA暴露患者的这种风险更大,似乎随着时间推移在增加,在确定这种疗法的风险和益处时应予以考虑。